{"name":"Corbus Pharmaceuticals","slug":"corbus","ticker":"CRBP","exchange":"NASDAQ","domain":"corbuspharma.com","description":"Corbus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for the treatment of severe inflammatory and autoimmune diseases. The company's lead product, Resunab, is an endocannabinoid system modulator being developed for the treatment of cystic fibrosis and systemic sclerosis. Corbus Pharmaceuticals has a strong pipeline of products in various stages of development, with a focus on oncology and ADCs.","hq":"Norwood, MA","founded":0,"employees":"N/A","ceo":"Yuval Cohen, PhD","sector":"Oncology / ADCs","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$154.48m","metrics":{"revenue":4822272,"revenueGrowth":97.6,"grossMargin":0,"rdSpend":70095000,"netIncome":-78537000,"cash":168195000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2018"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"Resunab patent cliff ($0.00 at risk)","drug":"Resunab","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Corbus Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Corbus Pharmaceuticals reported its financial results for the fourth quarter and full year 2023, with a net loss of $13.4 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"Corbus Pharmaceuticals Announces Collaboration with University of California, San Francisco","summary":"Corbus Pharmaceuticals announced a collaboration with the University of California, San Francisco to develop new treatments for inflammatory and autoimmune diseases.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"regulatory","headline":"Corbus Pharmaceuticals Receives Orphan Drug Designation for Resunab","summary":"Corbus Pharmaceuticals received orphan drug designation from the FDA for Resunab for the treatment of cystic fibrosis.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxONkk4bkRQNG1XcGpQRUp1UTd1Z2pjSEZINHpuYTA4cmVZbHdMSG5ySTgwejUxOV9XTjZsY2N3QjB4NjAwQm5UeGo4WDg1YUZtUDJoRXFVZzRKa2RJNlZUTEJTaWpEMS03dFkxM1JLalhuZGZtOEZzeW9Md2xSWllaR1FMN1MxMlBQb3NCVzg4XzhkMENmbUFjUHd6d09IYy1CYVV4c1BPX09UcTZSV3p2dFgzaUxqVGRiSHhVcGV5bFlRVmdyeHU5Sw?oc=5","date":"2026-04-07","type":"regulatory","source":"Benzinga","summary":"Corbus Offers Upside Despite Post-FDA Update, Analyst Highlights Competitive Edge - Corbus Pharmaceutical - Benzinga","headline":"Corbus Offers Upside Despite Post-FDA Update, Analyst Highlights Competitive Edge - Corbus Pharmaceutical","sentiment":"neutral"},{"date":"2026-04-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxNNURfcFhGWTRONllPZ1Z2REc3WWJTZ0RmSmhlVHZVbmdRNlQ3b1NUYTBDVTVrZENmc002Q3pjcUVnTjhrSWg0R3FBT2ExeVZDVjFtSTFPMWVQdnRkc1NVVkd2bHVNQjh0a2l5M29xSlZ3eXphRVBiY1pQbjk5cnZIMGZuRU5oVTFJMUk0bDVHTk1RUmRyOVFfemJ4cndKZXZCSS1DOG1XNUdTYkxsZUNxT2cyOUtwMm5nYXc?oc=5","date":"2026-03-18","type":"trial","source":"Stock Titan","summary":"Obesity drug from Corbus shows rapid weight loss in early trial - Stock Titan","headline":"Obesity drug from Corbus shows rapid weight loss in early trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPQ2VEa3M3N0ZrVmk3MWhkR0FDRDZHVU9fcE5LSGNCYkdyd3g3MHNVU3Y3amR6Nll1RnMyaTVpQlROTWg1ZDJJVjlpYlEybWxHYUhwcWY1ak9udWYwTy1mNmg3Z0lFT0FZUEp0SUhrWUJveE9tSk1mdmgzVWNKc1JXQkZEaTVWdkVRUkRXdEdOS2pqWW56OUZ5Wjh3Sl92OFg3akNGRk5JQWVWRFZhTnJpTnY1d1B1LVhacVRR?oc=5","date":"2026-03-09","type":"pipeline","source":"Stock Titan","summary":"Obesity drug shows 2.9% weight loss in 14 days at Corbus Pharma - Stock Titan","headline":"Obesity drug shows 2.9% weight loss in 14 days at Corbus Pharma","sentiment":"neutral"},{"date":"2026-03-09","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPekdJN0NzMmZFaUFWRnVndFVueHp4OWUzcTdUQXJmYzVTSG9zUWJtS0ZhUUI5NlVKM05MVkhoMUZkZjBwSXE2c2JXLXNZMXh0Y0V4UmNTRThPSXIzQVp5QmctOE9GVU54dFlDbXJ4ZXczREZNWnR0cnhxZTdZdjdfZVBGZzhhcDk1ZmpGcHJEV3VIcVpyb1JhNWZwdktBWE1CbXJSZ2p5LURSYXZiY3dxalEwWEdkaGFwdHhFckJXaEY4SWM?oc=5","date":"2026-01-22","type":"pipeline","source":"AD HOC NEWS","summary":"The Truth About Corbus Pharmaceuticals (CRBP): Hidden Small-Cap That Might Be a Game-Changer - AD HOC NEWS","headline":"The Truth About Corbus Pharmaceuticals (CRBP): Hidden Small-Cap That Might Be a Game-Changer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQdzRncktDNzRxX1JBNnQ4SDdQNDg4MFp6dWllRWozSHBDcnBDeUJ1c0R3TDZFd2dUYm1EVEhEb3FaMlVpT0Y2TmNxUWhxckR4QUdQdkxYTGJ2SjBZRzNCa092WHNLMDgxSVc4NjAtMkJSY2I2UXBlLVV5QVRtZW8xTXhBTTRac3FVYlFJS3lmbm4yLW56bUVFRDBhVmxOVWRLRlZxdWNkbVVGMTJiaHNJSkNIX3lfZw?oc=5","date":"2025-12-11","type":"trial","source":"Schaeffer's Investment Research","summary":"2 Pharma Stocks Pop on Strong Obesity Drug Trial Results - Schaeffer's Investment Research","headline":"2 Pharma Stocks Pop on Strong Obesity Drug Trial Results - Schaeffer's Investment Research","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxOQjRCQTl4a0Nfc3ZvQ1NERUd1eUY3WGxOd1Qxb3Z0Z3VaR2tWc21PbWlPS1dvUWhKVzJNMDMtSl8wVDNteFJreXpldnVYZy0tRi1BYjlaeGl4Qkx0TXhGRi1WU0NmdTJ4czZYRldEUTIzdjFaNlREQUZKdGZMenhRZy1oNERQbUZNQlBEVnRfbGx0Qng4eVY4Zk5QLWtnUllaVFo3cndhS3NJMjRLeWNTUDgxYjFCTmNsaGkzQXBB?oc=5","date":"2025-12-11","type":"trial","source":"Stock Titan","summary":"Corbus Pharma (NASDAQ: CRBP) reports safe Phase 1a CRB-913 data, launches 12-week obesity study - Stock Titan","headline":"Corbus Pharma (NASDAQ: CRBP) reports safe Phase 1a CRB-913 data, launches 12-week obesity study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNMDl0VzEzX3plUXQ4Ql9FZXg0RldmQlpRWFNyQ2p3TnA1Vi1KaGdUYVZPQmM4YzFucWV2NHBPcTJGQ0loUkdrakhfWUNaOXUyVURVVk1vZVdJVy1QLW5NaFRVSWtSVWFPVk54dDlOUUVNUjQyT3VSTmJEYU50dXN2cmZJTEJPckNjT09wbUNXZU9LRTVlMjFtYjlKNVpnUGZjd3lrZnhiTGJ0Ym55bl90eFI0eVVyYVZEemlZ?oc=5","date":"2025-12-10","type":"trial","source":"Quiver Quantitative","summary":"Corbus Pharmaceuticals to Announce Phase 1a Results for CRB-913 on December 11, 2025 | CRBP Stock News - Quiver Quantitative","headline":"Corbus Pharmaceuticals to Announce Phase 1a Results for CRB-913 on December 11, 2025 | CRBP Stock News","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOWF9XVTJWZ3Zoc1Q2Z0V2b2NiTWp3S0RiU2V4N2M5MmVTekpiTW44bzhORGY4Z0h5QlpDS1ZJdmQxWDdzYTA5NklsZl9Kd1ZROHB6cGxaMmx5X3BReHdhd2tLRXZ3cmhhR251SmEydFE2NlgyTm5COE44WFpLVHR5SEU3X2NoN2FYMzZMNF90WjVybzliZ09feGdRNE5RUzhzWmtXNVBkYzlUWG1hMTdyYzZKc1pSWkE?oc=5","date":"2025-06-17","type":"trial","source":"Seeking Alpha","summary":"Corbus Pharmaceuticals: Is Its Pipeline Really Worthless After Novo's Negative Data? - Seeking Alpha","headline":"Corbus Pharmaceuticals: Is Its Pipeline Really Worthless After Novo's Negative Data?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxOeXNNOWV0S0VCYUFlcTVLbldwd2dEbkdkTi1feU5SSkMxMEx6UGlkbjRjenZxMkU0QlVYZkp6ODA2cEY2aENHTEtSeEVjbEFJaHU3RkFyamVpYk85RmZoeUtzTDJ5Y3h5cXpuaXRxek82SUJHb29xU0JGcGMyOVFrVTJB?oc=5","date":"2025-05-16","type":"pipeline","source":"Yahoo Finance","summary":"Is Small-Cap Corbus Pharma a Worthy Cannabis Investment? - Yahoo Finance","headline":"Is Small-Cap Corbus Pharma a Worthy Cannabis Investment?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNWjhaWXZ6Q1EyLVQ0RUYtazc3SnlqZEdXc1NaODVIZ2d4LVNaS2EwUmZTeWlLSnNUU1VYM0g0N0lMaExJRXRaR2lYeERHTmk0MjlDd2VkVnRQRTB6OEQwXzBXRVJKOGY4dTY5eGJOb3g1U1JaOGpraDRmcVFmWXFnYmxkNkREWk5MdGNBTUxQLS1KSnR4Y1hvTWFXQnlqWnFGSHZlQTEzUVZTTThj?oc=5","date":"2024-09-20","type":"pipeline","source":"Investor's Business Daily","summary":"Novo, Corbus Dive After Obesity Drug Causes Psychiatric Effects - Investor's Business Daily","headline":"Novo, Corbus Dive After Obesity Drug Causes Psychiatric Effects - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE05NGlPWG5xTWNZMXVQX2hQVkpPVHNFcWJ0TEptV2xJLXlsSDhLRG4wX09Ubjdyb2Y5WUtMUUVKRUxvZndFYnpIVXRMZVgyQzQ4?oc=5","date":"2024-01-26","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"}],"patents":[{"drugName":"Resunab","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol-Myers Squibb","Merck & Co.","Johnson & Johnson"],"therapeuticFocus":["Oncology","ADCs"],"financials":{"source":"sec_edgar+yahoo","revenue":4822272,"revenuePeriod":"2018-12-31","revenueHistory":[{"value":4822272,"period":"2018-12-31"},{"value":2440195,"period":"2017-12-31"},{"value":2440195,"period":"2017-12-31"},{"value":796312,"period":"2017-09-30"},{"value":350186,"period":"2017-06-30"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":70095000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-78537000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":168195000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}